Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Latest News

BioVaxys Technology Corp. Announces Failure to File Cease Trade Order

Published

on

VANCOUVER, BC, May 16, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) announces that the Ontario Securities Commission (the “OSC“) has issued a failure to file cease trade order (“FFCTO“) under National Policy 11-207 Failure-to-File Cease Trade Orders and Revocations in Multiple Jurisdictions (“NP 11-207“), prohibiting the trading by any person of any securities of the Company in Canada, including trades in the Company’s common shares made through the Canadian Securities Exchange.

The FFCTO was issued as a result of the delay in filing the Company’s audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“) and interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024, and the Required Interim Filings were required to be made no later than April 1, 2024.

The OSC had previously granted, on February 29, 2024, a management cease trade order, which has been been revoked and replaced by the FFCTO dated May 15, 2024.

The Company is working diligently to facilitate the completion of the Required Annual Filings and the Required Interim Filings and expects to be in a position to file in the very near future. The Company anticipates that the FFCTO will remain in place until such time as the Required Annual Filings and Required Interim Filings are filed and the OSC subsequently revokes the FFCTO.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and its HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.

ON BEHALF OF THE BOARD

Signed “James Passin
James Passin, Chief Executive Officer
Phone: +1 646 452 7054

Cautionary Statements Regarding Forward Looking Information

This news release contains certain “forward-looking information” and “forward-looking statements” (collectively “forward-looking statements”) within the meaning of applicable securities legislation. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “estimates”, “potential”, “possible”, and similar expressions, or statements that events, conditions, or results “will”, “may”, “could”, or” should” occur or be achieved. All statements, other than statements of historical fact, included herein, without limitation, statements relating to the Required Annual Filings and the Required Interim Fillings, including the ability of the Company to file the Required Annual Filings and the Required Interim Fillings by the timeline set out in this news release and any revocation of the FFCTO are forward-looking statements. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates that, while considered reasonable by the Company, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation, the ability of the Company to complete its audit and file the Required Annual Filings and, subsequently, its Required Interim Filings as currently anticipated, the Company’s ability to advance its business plans and the results thereof, continued availability of capital, and changes in general economic, market and business conditions. Readers should not place undue reliance on the forward-looking statements and information contained in this news release concerning these items. The Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by applicable securities laws.

Logo: https://mma.prnewswire.com/media/2415135/BioVaxys_Technology_Corp_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-announces-failure-to-file-cease-trade-order-302148051.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Latest News

Teal secures $8M seed funding for groundbreaking accounting solution

Published

on

 

Teal has announced a significant milestone in its journey to transform SMB accounting with the closure of an $8 million seed funding round.

According to TechFundingNews, the company, which focuses on providing accounting infrastructure for Vertical SaaS businesses, aims to address the critical need for integrated financial solutions within various platforms.

Founded by industry veterans Ian Crosby and Adam Saint, Teal stands out in the FinTech landscape for its unique approach to accounting services. Leveraging their expertise from founding Bench Accounting and working at Shopify, Crosby and Saint have developed a platform that empowers Vertical SaaS businesses to offer customised accounting suites to their SMB customers.

One of the key challenges faced by SMBs is the lack of seamless accounting solutions integrated into their core business platforms. Teal aims to bridge this gap by equipping companies with the necessary APIs and tools to build their own accounting offerings. This enables SMBs to access crucial insights such as real-time cash flow, per-product profitability, and streamlined tax filing processes.

Teal’s comprehensive suite of out-of-the-box tools enables Vertical SaaS companies to launch their accounting platforms swiftly, often in as little as four weeks. These tools include fully functioning app code repositories and seamless data integrations with external sources like Plaid, enhancing the overall user experience for SMBs.

According to Ian Crosby, Co-Founder and CEO of Teal, the company’s vision is to become the “Stripe for accounting,” providing the foundational infrastructure for Vertical SaaS companies to embed accounting features seamlessly. By integrating accounting software directly into their platforms, businesses can enhance customer engagement and drive adoption of financial services features.

The significance of Teal’s innovative approach has not gone unnoticed in the investment landscape. Torch Capital, a leading investor in tools and platforms for SMBs, led the recent $8 million seed funding round. Partner Katie Reiner expressed enthusiasm for Teal’s mission to revolutionize the SMB accounting space, citing the dire need for intuitive and streamlined accounting tools.

In an era where embedded finance is gaining traction, Teal’s commitment to offering tailored accounting solutions signifies a promising step towards empowering SMBs with the financial tools they need to thrive in today’s competitive landscape.

Source: fintech.global

The post Teal secures $8M seed funding for groundbreaking accounting solution appeared first on HIPTHER Alerts.

Continue Reading

Latest News

Digital China’s Guo Wei Shares ‘China’s Sample’ of Global Digital Innovation with London Business School

Published

on

LONDON, May 22, 2024 /PRNewswire/ — On May 21st, at the invitation of London Business School (LBS), Guo Wei, Chairman of Digital China, participated in the esteemed “Managing the Digital Organization” lecture, engaging with a cohort of prospective business leaders. Focusing on the trending topics of ‘Artificial Intelligence’ and ‘Digital Transformation’, he imparted the digital philosophy and practices of Chinese enterprises amidst the digital civilization era.

Digital China, a prominent player in China’s digital economy, has harnessed over two decades of deep involvement in the nation’s information industry to embrace the power of digitization. This has culminated in what Guo Wei refers to as ‘China’s Vibrant Blueprint for Digital Transformation’, carving a distinctive path of digital metamorphosis. Notably, Digital China’s transformation narrative has been incorporated into LBS’s esteemed case library, underscoring its significance as a teaching instrument.

In his lecture, Guo Wei emphasized that the digital economy now constitutes the backbone of supply, with digital technology emerging as the paramount catalyst for economic expansion. The hastening pace of global digitization propels us into an epoch of digital civilization. For multinational corporations, digital strategies have escalated to the status of corporate strategy, and the amassing of data assets constitutes the pivotal lever for business innovation. Amidst this evolution, AI-fueled digital-cloud integration signifies a disruptive technological innovation, poised to invigorate the global landscape. Digital China feels honored to reprise its role in elite international business school case repositories, thereby contributing insights to academia. This recognition signifies that Chinese enterprises’ digital and AI acumen resonates globally, exemplifying world-class practices.

Professor Julian Birkinshaw, Vice Dean and Professor of Strategy and Entrepreneurship at LBS, remarked, “As a global institution, we constantly seek out exemplary cases worldwide. Digital China was chosen not solely due to its prominence in China but also its sophisticated implementation of digital technologies, demonstrating adaptability and offering invaluable insights to our students about the contemporary business milieu. The story of Digital China encapsulates Mr. Guo Wei’s philosophy – digitization transcends being a mere process; it embodies the existential rationale for companies. This philosophy underpins our decision to feature Digital China in our case studies.”

Photo – https://mma.prnewswire.com/media/2419014/Digital_China_s_Guo_Wei_Professor_Julian_Birkinshaw.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/digital-chinas-guo-wei-shares-chinas-sample-of-global-digital-innovation-with-london-business-school-302152277.html

Continue Reading

Latest News

Endava partners with Finexos to revolutionise AI-driven credit risk management

Published

on

 

Endava, a leading technology services company combining world-class engineering, industry expertise, and a people-centric mindset, has announced its partnership with Finexos, an AI-powered credit risk and analytics platform.

The partnership aims to leverage Finexos’ state-of-the-art credit risk engine to enhance credit decisioning processes, significantly increasing the accuracy of suitability and affordability calculations for banks and lenders. This collaboration will enable more borrowers to access affordable credit while reducing non-performing loans and improving capital allocation.

Endava, with over 20 years of industry expertise, helps financial institutions position their products and services at the forefront of innovation. Through world-class engineering, Endava supports customers in meeting the demands of responsible lending.

Finexos offers a unique methodology to improve credit decisioning, making it possible for larger volumes of borrowers to access affordable credit. Their advanced AI-powered software helps reduce default risks and improve capital allocation for lenders.

The collaboration allows Endava to integrate Finexos’ AI credit decisioning software into their services, helping financial institutions provide responsible lending solutions. This integration aims to increase accessibility for a broader range of customers and provide a more accurate assessment of borrower risk.

Finexos’ cost-effective data science SaaS platform enriches data analysis, speeds up decisions for borrowers, and reduces costs for lenders. The platform operates without geographical constraints, works within institutions’ firewalls, and ensures data security by not accepting or requiring personally identifiable information (PII).

Endava’s head of alliances and partnerships Lewis Brown said, “The addition of Finexos strengthens Endava’s banking ecosystem with new and existing AI-based software and also brings to our clients new tools that fuel growth and react to new and future regulatory requirements.”

Matthew Williamson, SVP & industry principal at Endava, mentioned, “At Endava, we are delighted to announce our partnership with Finexos, demonstrating our ongoing commitment to financial inclusion. This relationship authentically aligns with our core values, using technology and democratising access to financial instruments. Giving individuals and communities the ability to access fair, consistent next-gen real-time credit scoring. Empowering economic growth and stimulus.”

Source: fintech.global

The post Endava partners with Finexos to revolutionise AI-driven credit risk management appeared first on HIPTHER Alerts.

Continue Reading

Trending